Karafillakis Emilie, Hassounah Sondus, Atchison Christina
WHO Collaborating Centre for Public Health Education and Training, Imperial College, London W6 8RP, UK.
Department of Primary Care and Public Health, School of Public Health, Imperial College, London W6 8RP, UK.
Vaccine. 2015 Apr 27;33(18):2097-107. doi: 10.1016/j.vaccine.2015.03.016. Epub 2015 Mar 18.
Prior to the introduction of rotavirus vaccines in 2006, rotavirus was the leading cause of severe gastroenteritis among European children <5 years of age. We conducted a systematic review of the published literature to examine the effectiveness and impact of rotavirus vaccines in Europe following the first eight years of routine use. Four publication databases were searched, yielding 276 unique citations from February 1st, 2006 to July 31st, 2014. Twenty four studies on effectiveness (n=9) and impact (n=15) met the inclusion criteria. Across Europe, vaccine effectiveness against rotavirus-related healthcare utilisation ranged from 68% to 98%, consistent with efficacy data from clinical trials. Reductions in rotavirus hospitalisations ranged from 65% to 84%, consistent with findings from post-marketing studies from the US and Latin America. We confirm the significant public health benefit of rotavirus vaccination in Europe and provide further evidence to support implementation of universal rotavirus vaccination in all European countries.
在2006年引入轮状病毒疫苗之前，轮状病毒是欧洲5岁以下儿童严重胃肠炎的主要病因。我们对已发表的文献进行了系统综述，以研究轮状病毒疫苗在常规使用的头八年之后在欧洲的有效性和影响。检索了四个出版物数据库，从2006年2月1日至2014年7月31日共获得276条独特的引文。24项关于有效性（n = 9）和影响（n = 15）的研究符合纳入标准。在整个欧洲，轮状病毒疫苗预防与轮状病毒相关的医疗保健利用的有效性范围为68%至98%，与临床试验的疗效数据一致。轮状病毒住院人数的减少幅度为65%至84%，与美国和拉丁美洲的上市后研究结果一致。我们证实了轮状病毒疫苗在欧洲具有显著的公共卫生效益，并提供了进一步的证据来支持在所有欧洲国家实施普遍的轮状病毒疫苗接种。
